| Literature DB >> 31881890 |
Elham Karimizadeh1, Ali Sharifi-Zarchi2, Hassan Nikaein3, Seyedehsaba Salehi4, Bahar Salamatian4, Naser Elmi1, Farhad Gharibdoost1, Mahdi Mahmoudi5,6.
Abstract
BACKGROUND: Systemic sclerosis (SSc), a multi-organ disorder, is characterized by vascular abnormalities, dysregulation of the immune system, and fibrosis. The mechanisms underlying tissue pathology in SSc have not been entirely understood. This study intended to investigate the common and tissue-specific pathways involved in different tissues of SSc patients.Entities:
Keywords: Common pathway; Functional analysis; Integrative gene expression analysis; Systemic sclerosis
Mesh:
Substances:
Year: 2019 PMID: 31881890 PMCID: PMC6935135 DOI: 10.1186/s12920-019-0632-2
Source DB: PubMed Journal: BMC Med Genomics ISSN: 1755-8794 Impact factor: 3.063
Fig. 1Flowchart of methods
Characteristics of datasets included in this study
| First Author | Tissue | GEO Accession | Reference |
|---|---|---|---|
| Christmann R | Lung | GSE81292 | [ |
| Feghali-Bostwick CA | Lung | GSE48149 | – |
| Christmann R | Lung | GSE76808 | [ |
| Pendergrass S | PBMC | GSE19617 | [ |
| Risbano MG | PBMC | GSE22356 | [ |
| Cheadle C | PBMC | GSE33463 | [ |
| Pendergrass S | Skin | GSE32413 | [ |
| Hinchcliff M | Skin | GSE45485 | [ |
| Milano A | Skin | GSE9285 | [ |
| Whitfield ML | Skin | GSE76807 | – |
Abbreviation: GEO: Gene Expression Omnibus; PBMC: peripheral blood mononuclear cell
Shared DEGs between pair tissues
| Pair tissues | Shared DEGs |
|---|---|
| lung - PBMC | |
| lung - skin | |
| PBMC - skin |
Abbreviation: DEGs: Differentially Expressed Genes
Most significant GO and KEGG pathways enriched in lung clusters
| Go Biological Process | KEGG Pathway | ||
|---|---|---|---|
| cluster L.1 (Inflammation & immunity) – size/DEGs = 56/54 | |||
| - cytokine-mediated signaling pathway | 1.65E-17 | - Cytokine-cytokine receptor interaction | 5.61E-22 |
| - inflammatory response | 3.73E-11 | - Hematopoietic cell lineage | 1.05E-10 |
| - cellular response to cytokine stimulus | 1.25E-12 | - Chemokine signaling pathway | 2.66E-09 |
| - chemokine-mediated signaling pathway | 2.78E-10 | - JAK-STAT signaling pathway | 1.06E-08 |
| - positive regulation of leukocyte migration | 6.87E-08 | - TNF signaling pathway | 3.78E-07 |
| cluster L.2 (Inflammation & immunity) – size/DEGs = 48/47 | |||
| - regulation of transcription from RNA polymerase II promoter | 1.92E-12 | - MAPK signaling pathway | 1.48E-09 |
| - positive regulation of transcription from RNA polymerase II promoter | 1.04E-10 | - TNF signaling pathway | 1.04E-05 |
| - positive regulation of transcription, DNA-templated | 6.58E-10 | - Osteoclast differentiation | 2.04E-05 |
| - regulation of cell cycle | 1.13E-08 | - Inflammatory bowel disease (IBD) | 0.000298 |
| - regulation of transcription, DNA-templated | 7.42E-06 | - Amphetamine addiction | 0.000298 |
| cluster L.3 (Cell proliferation & cell death) - size/DEGs = 20/19 | |||
| - positive regulation of cyclin-dependent protein serine/threonine kinase activity | 0.000225 | - p53 signaling pathway | 1.44E-07 |
| - positive regulation of cell cycle | 0.000225 | - Cell cycle | 1.4E-06 |
| - mitotic cell cycle phase transition | 0.000225 | - FoxO signaling pathway | 6.39E-05 |
| - G1/S transition of mitotic cell cycle | 0.000225 | - Progesterone-mediated oocyte maturation | 0.000704 |
| - cell cycle G2/M phase transition | 0.000284 | - Oocyte meiosis | 0.001103 |
| cluster L.4 (GPCR signaling) - size/DEGs = 9/9 | |||
| - adenylate cyclase-activating G-protein coupled receptor signaling pathway | 5.98E-17 | - Neuroactive ligand-receptor interaction | 7.6E-09 |
| - adenylate cyclase-modulating G-protein coupled receptor signaling pathway | 2.53E-15 | - Regulation of lipolysis in adipocytes | 0.001669 |
| - cAMP-mediated signaling | 1.11E-11 | - Renin secretion | 0.001669 |
| - G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | 4.58E-08 | - Salivary secretion | 0.002418 |
| - positive regulation of cAMP metabolic process | 5.94E-06 | - Vascular smooth muscle contraction | 0.003501 |
| cluster L.5 (GPCR signaling) - size/DEGs = 19/19 | |||
| - regulation of small GTPase mediated signal transduction | 1E-10 | - Axon guidance | 0.006298 |
| - regulation of intracellular signal transduction | 3.27E-07 | ||
| - regulation of actin filament-based process | 2.44E-05 | ||
| - regulation of cell migration | 2.44E-05 | ||
| - regulation of actin cytoskeleton organization | 3.37E-05 | ||
| cluster L.6 (ECM organization) - size/DEGs = 13/11 | |||
| - extracellular matrix organization | 3.55E-11 | - Protein digestion and absorption | 1.08E-15 |
| - collagen fibril organization | 1.56E-07 | - AGE-RAGE signaling pathway in diabetic complications | 6.03E-05 |
| - protein complex subunit organization | 6.15E-07 | - Amoebiasis | 6.03E-05 |
| - skeletal system development | 6.58E-07 | - ECM-receptor interaction | 6.03E-05 |
| - skin development | 6.58E-07 | - Platelet activation | 8.48E-05 |
| cluster L.7 (Metabolic process) - size/DEGs = 8/7 | |||
| - secondary alcohol biosynthetic process | 1.83E-08 | - Terpenoid backbone biosynthesis | 5.16E-07 |
| - cholesterol biosynthetic process | 1.83E-08 | - Synthesis and degradation of ketone bodies | 2.52E-05 |
| - sterol biosynthetic process | 1.87E-08 | - Steroid biosynthesis | 7.07E-05 |
| - cholesterol metabolic process | 1.19E-07 | - Metabolic pathways | 8.42E-05 |
| - acetyl-CoA metabolic process | 2.02E-07 | - Butanoate metabolism | 8.42E-05 |
| cluster L.8 (Regulation of BMPs) - size/DEGs = 20/20 | |||
| - regulation of BMP signaling pathway | 5.24E-11 | - Signaling pathways regulating pluripotency of stem cells | 1.69E-09 |
| - BMP signaling pathway | 4.87E-08 | - Hedgehog signaling pathway | 1.8E-08 |
| - cellular response to BMP stimulus | 5E-08 | - Basal cell carcinoma | 1.96E-08 |
| - regulation of ossification | 5.47E-08 | - Hippo signaling pathway | 4.83E-08 |
| - positive regulation of cartilage development | 2.94E-07 | - TGF-beta signaling pathway | 8E-06 |
| cluster L.9 (Metabolic process) - size/DEGs = 11/11 | |||
| - keratan sulfate catabolic process | 0.00139 | - Phospholipase D signaling pathway | 0.001041 |
| - keratan sulfate metabolic process | 0.002787 | - Rap1 signaling pathway | 0.001615 |
| - sulfur compound catabolic process | 0.002787 | - cAMP signaling pathway | 0.029672 |
| - keratan sulfate biosynthetic process | 0.002787 | - Ras signaling pathway | 0.029672 |
| - glycosaminoglycan catabolic process | 0.005613 | ||
| cluster L.10 (GPCR signaling) - size/DEGs = 22/21 | |||
| - axon guidance | 0.00022 | - Axon guidance | 1.8E-07 |
| - transmembrane receptor protein tyrosine kinase signaling pathway | 0.000396 | - Focal adhesion | 0.0014420.011273 |
| - axonogenesis | 0.000396 | - Primary immunodeficiency | 0.032572 |
| - cell migration involved in sprouting angiogenesis | 0.007527 | - B cell receptor signaling pathway | |
| - ephrin receptor signaling pathway | 0.007527 | ||
| cluster L.11 (ECM degradation) - size/DEGs = 23/23 | |||
| - proteolysis | 0.000176 | None | |
| - extracellular matrix disassembly | 0.00022 | ||
| - regulation of endopeptidase activity | 0.005145 | ||
| - extracellular matrix organization | 0.007401 | ||
| - regulation of membrane protein ectodomain proteolysis | 0.014697 | ||
| cluster L.12 (Inflammation and immunity) - size/DEGs = 12/11 | |||
| - neutrophil degranulation | 0.004647 | - Insulin secretion | 0.010314 |
| - neutrophil mediated immunity | 0.004647 | - Osteoclast differentiation | 0.012295 |
| - neutrophil activation involved in immune response | 0.004647 | ||
| - potassium ion transport | 0.014375 | ||
| - metal ion transport | 0.027277 | ||
Abbreviation: GPCR: G-protein coupled receptor; BPMs: Bone morphogenetic proteins
Most significant GO and KEGG pathways enriched in PBMC clusters
| Go Biological Process | KEGG Pathway | ||
|---|---|---|---|
| Cluster P.1 (Inflammation and immunity) - size/DEGs = 7/7 | |||
| - type I interferon signaling pathway | 1.16E-07 | None | |
| - cellular response to type I interferon | 1.16E-07 | ||
| - endosomal vesicle fusion | 0.000119 | ||
| - cytokine-mediated signaling pathway | 0.000503 | ||
| - negative regulation of viral genome replication | 0.001647 | ||
| Cluster P.2 (Inflammation and immunity) - size/DEGs = 9/9 | |||
| - response to organophosphorus | 5.96E-06 | - Apoptosis | 1.16E-07 |
| - response to purine-containing compound | 5.96E-06 | - Osteoclast differentiation | 6.68E-06 |
| - response to cytokine | 1.34E-05 | - TNF signaling pathway | 0.000265 |
| - cellular response to organic substance | 1.34E-05 | - Influenza A | 0.000798 |
| - response to cAMP | 2.61E-05 | - Viral carcinogenesis | 0.001022 |
Most significant GO and KEGG pathways enriched in skin clusters
| Go Biological Process | KEGG Pathway | ||
|---|---|---|---|
| cluster S.1 (ECM organization) - size/DEGs = 11/11 | |||
| - extracellular matrix organization | 9.32E-10 | - Protein digestion and absorption | 7.46E-09 |
| - skeletal system development | 5.4E-07 | - ECM-receptor interaction | 5.35E-05 |
| - eye morphogenesis | 6.6E-06 | - Focal adhesion | 0.000526 |
| - collagen fibril organization | 1.51E-05 | - PI3K-Akt signaling pathway | 0.001831 |
| - eye development | 3.74E-05 | ||
| cluster S.2 (Inflammation and immunity) - size/DEGs = 14/14 | |||
| - inflammatory response | 3.4E-06 | - Legionellosis | 3.16E-06 |
| - neutrophil mediated immunity | 5.53E-05 | - Pertussis | 5.59E-06 |
| - cellular response to cytokine stimulus | 5.53E-05 | - Rheumatoid arthritis | 7.79E-06 |
| - response to lipopolysaccharide | 0.000268 | - TNF signaling pathway | 1.31E-05 |
| - positive regulation of apoptotic cell clearance | 0.000619 | - Phagosome | 4.02E-05 |
| cluster S.3 (ECM organization) - size/DEGs = 7/7 | |||
| - platelet degranulation | 1.5E-08 | - Complement and coagulation cascades | 0.002555 |
| - regulated exocytosis | 1.83E-08 | ||
| - extracellular matrix organization | 1.08E-07 | ||
| - post-translational protein modification | 0.003869 | ||
| - extracellular matrix disassembly | 0.005238 | ||
| cluster S.4 (Inflammation and immunity) - size/DEGs = 5/5 | |||
| - type I interferon signaling pathway | 0.001321 | - RIG-I-like receptor signaling pathway | 0.01738 |
| - negative regulation of viral genome replication | 0.001321 | ||
| - negative regulation of viral life cycle | 0.001321 | ||
| - cellular response to type I interferon | 0.001321 | ||
| - regulation of viral genome replication | 0.001321 | ||
Fig. 2Boxplots of data before and after batch effect correction. a) Boxplot of PBMC data before batch effect removal. b) Boxplot of PBMC data after batch effect removal. c) Boxplot of lung data before batch effect removal. d) Boxplot of lung data after batch effect removal. e) Boxplot of skin data before batch effect removal. f) Boxplot of skin data after batch effect removal. Different datasets were displayed in different colors
Fig. 3Lung PPI network. Twelve distinct functional clusters were detected in lung tissue. Each cluster is a set of highly-connected nodes and is illustrated in a discrete color
Fig. 4a) PBMC PPI network. Two distinct functional clusters were identified in PBMC. b) Skin PPI network. Four distinct functional clusters were detected in skin tissue. Each cluster is a set of highly-connected nodes and is illustrated in a discrete color
shared pathway and its related genes in three investigated tissues
| Tissue | Cluster Name | Shared Pathway | Genes |
|---|---|---|---|
| Lung | cluster L.1 | TNF signaling | |
| cluster L.2 | TNF signaling | ||
| PBMC | cluster P.2 | TNF signaling | |
| Skin | cluster S.2 | TNF signaling |